(RTTNews) - Hemab Therapeutics Holdings, Inc. (COAG), a clinical-stage biotechnology company developing therapies for blood coagulation disorders, reported on Thursday that it has dosed first participant in a Phase 1 trial of HMB-003, an investigational peptide therapy for heavy